421
On 24 May 2006, a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation number 369. The active ingredient is Bilayer engineered skin composed of keratinocytes from the patient (autologous) and fibroblasts from a donor (allogeneic) embedded in a plasma matrix for treatment of epidermolysis bullosa.